These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 14619524

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
    Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M.
    Prostate; 2004 Aug 01; 60(3):205-13. PubMed ID: 15176050
    [Abstract] [Full Text] [Related]

  • 23. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y, Aketa K, Nabeta C, Nakanishi K, Kamiguchi K, Mano Y, Kitamura H, Kobayashi J, Tsukahara T, Shijubo N, Sato N.
    Clin Cancer Res; 2005 Feb 01; 11(3):1000-9. PubMed ID: 15709165
    [Abstract] [Full Text] [Related]

  • 24. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y, Okugawa T, Furugen R, Nagata Y, Takahashi Y, Wang L, Ikeda H, Watanabe M, Imai S, Shiku H.
    Int J Cancer; 2000 Aug 15; 87(4):553-8. PubMed ID: 10918197
    [Abstract] [Full Text] [Related]

  • 25. Identification of HLA-A24-binding peptides of Mycobacterium tuberculosis derived proteins with beta 2m linked HLA-A24 single chain expressing cells.
    Ding J, Wang Y, Cheng T, Chen X, Gao B.
    Immunol Invest; 2010 Jan 15; 39(2):103-13. PubMed ID: 20136618
    [Abstract] [Full Text] [Related]

  • 26. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K.
    Cancer Res; 1999 Aug 15; 59(16):4056-63. PubMed ID: 10463607
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K.
    Prostate; 2003 Oct 01; 57(2):152-9. PubMed ID: 12949939
    [Abstract] [Full Text] [Related]

  • 31. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.
    Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Wang Q, Greene MI, Hasegawa T, Hirata K, Asaka M, Sato N.
    Exp Mol Pathol; 2011 Feb 01; 90(1):55-60. PubMed ID: 20950610
    [Abstract] [Full Text] [Related]

  • 32. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T.
    Breast Cancer Res Treat; 2004 Nov 01; 88(1):29-41. PubMed ID: 15538043
    [Abstract] [Full Text] [Related]

  • 33. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
    Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R.
    Int J Cancer; 1998 Oct 05; 78(2):202-8. PubMed ID: 9754653
    [Abstract] [Full Text] [Related]

  • 34. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
    Mimura K, Kono K, Southwood S, Fikes J, Takahashi A, Miyagawa N, Sugai H, Fujii H.
    Cancer Immunol Immunother; 2006 Nov 05; 55(11):1358-66. PubMed ID: 16435129
    [Abstract] [Full Text] [Related]

  • 35. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
    Borghan MA, Oka S, Takiguchi M.
    Tissue Antigens; 2005 Oct 05; 66(4):305-13. PubMed ID: 16185326
    [Abstract] [Full Text] [Related]

  • 36. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
    Xu Y, Zhu KJ, Chen XZ, Zhao KJ, Lu ZM, Cheng H.
    Arch Dermatol Res; 2008 Jun 05; 300(5):235-42. PubMed ID: 18299861
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J, Latouche JB, Ma C, Sadelain M.
    Cancer Res; 2005 Jun 15; 65(12):5417-27. PubMed ID: 15958591
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.